Last reviewed: June 8, 2026
Last updated: June 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has become one of the most effective weight loss medications available, with clinical trials showing average weight loss of 15% over 68 weeks. However, eligibility depends on your medical history, current health status, and individual risk factors. PlexusDx helps you understand whether semaglutide is appropriate for your unique situation before beginning treatment.
Who Typically Qualifies for Semaglutide Treatment
Semaglutide is indicated for people with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher who have at least one weight-related health condition like type 2 diabetes, high blood pressure, or sleep apnea. Most candidates are adults aged 18 and older seeking sustainable weight loss when diet and exercise alone have not produced adequate results. PlexusDx serves patients across all 50 states without requiring insurance, making compounded semaglutide accessible to a wider range of individuals who may not qualify through traditional healthcare channels.
Your baseline metabolic health matters significantly. People with stable kidney function, normal thyroid function, and no active malignancy are generally better candidates for semaglutide therapy. PlexusDx conducts a comprehensive health intake to identify any red flags that might suggest semaglutide is not appropriate for your situation. This screening process takes into account not just your weight, but your overall metabolic picture.
Medical Conditions That May Restrict Semaglutide Use
A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) is an absolute contraindication to semaglutide use, since GLP-1 receptor activation may promote thyroid C-cell growth. Similarly, individuals with a history of acute pancreatitis or chronic pancreatitis should avoid semaglutide unless specifically cleared by their physician. Severe gastroesophageal reflux disease (GERD), gastroparesis, or inflammatory bowel disease may also warrant caution, as semaglutide slows gastric emptying and can worsen certain gastrointestinal conditions.
Pregnancy and breastfeeding are periods when semaglutide should not be used, as animal studies suggest potential developmental risks. People with severe kidney disease (eGFR below 15) or those on dialysis require extra oversight, though semaglutide is not completely contraindicated at higher kidney disease stages. PlexusDx providers review medication lists and medical history to flag any interactions or contraindications before you start treatment.
How Genetic Factors Influence Semaglutide Candidacy
Your genetic makeup plays a role in how well you respond to semaglutide and which dose you may need. The Precision Peptide Genetic Test available at PlexusDx analyzes key genetic variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—markers that influence your appetite regulation and metabolic response to GLP-1 therapy. This test maps 14 metabolic pathways and 49 peptides across 150+ genetic insights, helping predict your individual response pattern before committing to a specific medication or dose.
Some patients carry genetic variants that make them hyperresponders to semaglutide, meaning they experience rapid weight loss and may tolerate higher doses well. Others have genetic profiles suggesting slower metabolic adaptation, which might indicate a microdose GLP-1 protocol would be safer and more effective. Understanding your genetic predisposition allows PlexusDx to personalize your treatment from day one, rather than using a one-size-fits-all dosing approach. The test is available as a $99 add-on after your first month of treatment.
Medication Interactions and Drug Safety Considerations
Semaglutide can interact with several medications, particularly those that depend on rapid gastric transit or those affecting blood sugar. Sulfonylureas and insulin carry a heightened risk of hypoglycemia when combined with semaglutide, so dose adjustments are often needed. Certain oral diabetes medications, blood pressure drugs, and absorption-dependent medications (like oral contraceptives or warfarin) may require timing adjustments or monitoring. PlexusDx providers review your complete medication list and coordinate with your primary care team to ensure safe coadministration.
If you take medications for thyroid disease, blood thinners, or immunosuppressants, these require specific consideration before starting semaglutide. Some antidepressants and anti-anxiety medications may interact with GLP-1 therapy, particularly affecting appetite signals. Your PlexusDx health intake includes a detailed medication review to identify any potential conflicts and determine whether dose timing or additional monitoring is necessary for safe and effective treatment.
Why PlexusDx's Personalized Approach to Eligibility Works
Rather than applying rigid eligibility cutoffs, PlexusDx uses a layered assessment combining medical history, genetics, and medication review to create a personalized candidacy profile. This approach recognizes that two patients with the same BMI may have vastly different metabolic needs and risk profiles. Your dose may need to go up—your price won't—because PlexusDx charges a flat monthly rate of $149 or more for compounded semaglutide injection, regardless of dose escalation. This transparent pricing model removes barriers that might otherwise prevent someone from accessing appropriate therapy.
PlexusDx compounded semaglutide comes from licensed 503A compounding pharmacies and is available without insurance, membership fees, or geographic restrictions across all 50 states. Your eligibility determination happens through a straightforward consultation process that respects both safety and access. If semaglutide is not right for you, PlexusDx can discuss alternative options like oral semaglutide, tirzepatide, or the microdose GLP-1 protocol.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Am I eligible for semaglutide if I don't have diabetes or a diagnosed weight-related condition?
Yes. Semaglutide is approved for weight loss in people with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. However, eligibility also depends on your overall health, medication list, and any contraindications. PlexusDx evaluates each candidate individually to determine appropriateness.
What does the clinical evidence show about semaglutide's effectiveness?
Large clinical trials demonstrate that semaglutide produces average weight loss of 15% over 68 weeks when combined with lifestyle changes, significantly outperforming placebo and older weight loss medications. Response varies based on genetics, adherence, and individual metabolism, which is why PlexusDx offers genetic testing to predict your likely response pattern.
How much does PlexusDx compounded semaglutide cost, and is it covered by insurance?
PlexusDx compounded semaglutide injection starts at $149 per month and does not require insurance. The medication is HSA/FSA eligible, and pricing remains flat regardless of dose escalation. PlexusDx serves all 50 states with no membership fees.
What are the most common side effects, and who should avoid semaglutide because of them?
Nausea, vomiting, diarrhea, and constipation are common, especially during dose escalation, but typically decrease over time. People with severe gastroparesis, chronic pancreatitis, or a history of medullary thyroid carcinoma should not use semaglutide. Your PlexusDx provider screens for conditions that might make side effects intolerable or unsafe.
How can the Precision Peptide Genetic Test help determine if I'm a good candidate?
The test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to semaglutide and similar medications. It maps 150+ genetic insights across 49 peptides and 14 pathways, helping predict whether you'll be a strong responder or may benefit from a microdose approach, personalized from day one.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Much Weight Could I Lose on Ozempic? An In-Depth Look
How to Get a GLP-1 Without Insurance: Navigating Options for Affordable Access